CYP3A Variation, Premenopausal Estrone Levels, and Breast Cancer Risk
Nichola Johnson(Institute of Cancer Research), Olivia Fletcher(Breast Cancer Care), Claire Palles(University of Oxford), Minouk J. Schoemaker(Institute of Cancer Research), Julian Peto(London School of Hygiene & Tropical Medicine), Marketa Zvelebil(Institute of Cancer Research), Richard S. Houlston(Institute of Cancer Research), Michael E. Jones(Institute of Cancer Research), Michael J. Kerin(Ollscoil na Gaillimhe – University of Galway), Anthony J. Swerdlow(Institute of Cancer Research), Ian Tomlinson(University of Oxford), Gemma Simpson(King's College London), Sarah Chilcott-Burns(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research), Peter Broderick(Institute of Cancer Research), Elizabeth Folkerd(Royal Marsden Hospital), Elinor J. Sawyer(King's College London), Nick Orr(United States Department of Health and Human Services), Kate Walker(Royal College of Surgeons of England), Katarzyna Tomczyk(Institute of Cancer Research), Gillian Ross(Royal Marsden NHS Foundation Trust), Alan Ashworth(University of California, San Francisco), Ben P. Haynes(Institute of Cancer Research), Ben Coupland(Institute of Cancer Research), Lorna J. Gibson(London School of Hygiene & Tropical Medicine), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Jill Williamson(Institute of Cancer Research), Stephen G. Hillier(University of Pittsburgh)
Cited by 32
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k